ATS 2020: Taiwanese Experience of Durvalumab Consolidation in NSCLC Approaches That of Clinical Trials
Outcomes were superior among those with higher absolute lymphocyte counts
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.